Perrigo Makes Softgel Move As Mylan Continues Takeover Play
This article was originally published in The Tan Sheet
Executive Summary
Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.
You may also be interested in...
Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy
Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba
Perrigo’s New Papa: CEO Brings Product Development Know-How To Post
Joseph Papa brings 30 years of experience in healthcare and specialty generic pharmaceutical industries to his new position as president and CEO of Perrigo, the private-label manufacturer announced Sept. 11
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.